Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Orion Corporation
Deal Size : $0.6 million
Deal Type : Licensing Agreement
Searchlight Pharma Announces Suvexx® Launch in Europe, Along with Deal Expansion to all E.U. Markets
Details : The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U....
Brand Name : Suvexx
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 15, 2023
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Orion Corporation
Deal Size : $0.6 million
Deal Type : Licensing Agreement
Lead Product(s) : Sumatriptan
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Tonix Pharmaceuticals Holding Corp
Deal Size : $25.0 million
Deal Type : Acquisition
Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products
Details : Through the acquisition, Tonix gets two FDA approved products including, Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), indicated for the treatment of acute migraine in adults.
Brand Name : Zembrace SymTouch
Molecule Type : Small molecule
Upfront Cash : $22.0 million
July 03, 2023
Lead Product(s) : Sumatriptan
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Tonix Pharmaceuticals Holding Corp
Deal Size : $25.0 million
Deal Type : Acquisition
Lead Product(s) : Sumatriptan
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Tonix Pharmaceuticals Holding Corp
Deal Size : $25.0 million
Deal Type : Acquisition
Details : The acquisition of two currently-marketed products Zembrace SymTouch (sumatriptan succinate injection) and Tosymra (sumatriptan nasal spray), complement Tonix’s current intranasal clinical development program of TNX-1900 for migraine prevention.
Brand Name : Zembrace SymTouch
Molecule Type : Small molecule
Upfront Cash : $22.0 million
June 26, 2023
Lead Product(s) : Sumatriptan
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Tonix Pharmaceuticals Holding Corp
Deal Size : $25.0 million
Deal Type : Acquisition
Lead Product(s) : Sumatriptan
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cipla Receives Final Approvl for Generic Version of GlaxoSmithKline’s IMITREX®
Details : Cipla’s Sumatriptan Nasal Spray USP, 20 mg is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline’s Imitrex® Nasal Spray.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 02, 2021
Lead Product(s) : Sumatriptan
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Details : Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estoni...
Brand Name : Suvexx
Molecule Type : Small molecule
Upfront Cash : $2.0 million
December 21, 2020
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?